Neoplasms

All Conditions

Respiratory Tract (Lung and Bronchial) Diseases

Ear, Nose, and Throat Diseases

Mouth and Tooth Diseases

Rare Diseases

Carcinoma

Carcinoma, Squamous Cell

Laryngeal Diseases

Squamous Cell Carcinoma of Head and Neck

Hypopharyngeal Neoplasms

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Neoplasms, Squamous Cell

Head and Neck Neoplasms

Pharyngeal Neoplasms

Otorhinolaryngologic Neoplasms

Pharyngeal Diseases

Stomatognathic Diseases

Otorhinolaryngologic Diseases

Laryngeal Cancer

Hypopharyngeal Cancer

n=3. Injection of 0.05 mg/kg cRGD-ZW800-1, within 2 hours before imaging/surgery

n=3. Injection of 0.025 mg/kg cRGD-ZW800-1, within 2 hours before imaging/surgery

n=3. Injection of 0.01 mg/kg cRGD-ZW800-1, within 2 hours before imaging/surgery.

n=18: expansion cohort will be added to the group of patients that had received the selected dose in WP-I.

Intravenous administration of study drug at lesat 2h prior to surgery

CRGD-ZW800-1

Stijn Keereweer, MD, PhD

This is an open-label, single-dose, prospective clinical trial. The study comprises 2 work packages. The main objective of work package I (WP-1) is to assess feasibility of Fluorescence imaing (FLI) during total laryngectomy (TLE) and to assess the optimal dose of the cRGD-ZW800-1. Work package II (WP-II) is designed to assess whether FLI can detect and decrease tumor positive margins after a TLE.

This is a two staged clinical trial to investigate intraoperative fluorescence imaging in patientsundergoing TLE. WP-I is a dose finding study in which 2 doses will be tested with a possibility of a third dosing group. Every dosing cohort comprises 3 patients. After WP-I, an interim analysis will be performed to decide the optimal dose.

The optimal dose will be based on the TBR and the performance in detecting the most close margin (i.e. 'the sentinel margin'). A TBR of at least 1.5 is required for the optimal dose. If a positive margin is missed with fluorescence imaging, the concerned dose will be defined as suboptimal.

WP-II is an extension cohort of the optimal dose cohort selected in WP-I. WP-II will comprise of 18 patients.

The endpoints for WP-II are:

* the rate of tumor free resection margins based on the current golden standard;
* Sensitivity, specificity and positive predictive value of FLI;
* The intraoperative change in surgical management based on FLI;
* FLI of excised cervical lymph nodes;
* Influence of previous radiotherapy on the FLI performance;
* Adverse events and toxicity after intravenous injection with cRGD-ZW800-1;

The pathologist will be initially blinded during intraoperative assessment of the fresh surgical specimen.

Fluorescence-guided Surgery in Laryngeal- and Hypopharyngeal Cancer: a Feasibility Trial

The STELLAR Trial: Fluorescence-guided Surgery in Laryngeal- and Hypopharyngeal Cancer: a Feasibility Trial

Based on the tumor-to-background ratio (TBR) on breadloaves. Higher TBRs indicate a better outcome

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Fluorescence-guided Surgery in Laryngeal- and Hypopharyngeal Cancer: a Feasibility Trial	NCT05752149	Squamous Cell C... Squamous Cell C...	CRGD-ZW800-1	18 Years -	Erasmus Medical Center
Fluorescence-guided Surgery in Laryngeal- and Hypopharyngeal Cancer: a Feasibility Trial	NCT05752149	Squamous Cell C... Squamous Cell C...	CRGD-ZW800-1	18 Years -	Erasmus Medical Center

Spots Global Cancer Trial Database for tumour specific fluorescence imaging